| Speculative Drug Developers Take Aim at Blockbuster Status - SYS-CON Media (press release) |
|
|
SYS-CON Media (press release) Keryx Biopharmaceuticals develops pharmaceuticals for the treatment of diseases such as diabetes, renal disease and cancer. The company's oral, iron-based drug "Zerenex" is in phase III testing under a Special Protocol Assessment agreement with the FDA |